Anti Inflammatory Drugs Market Business Scenario, Size, Share, Growth, Insights, Industry Analysis, Trends and Forecasts Report 2030

The Global Anti-Inflammatory Drugs Market size reached USD 111.42 Billion in 2021 and is expected to register a revenue CAGR of 9.3% during the forecast period, according to latest analysis by Emergen Research. Potential pipeline candidates is the main factor driving the market revenue growth. For instance, the monoclonal antibody mirikizumab (LY3074828) fulfilled the primary and all significant secondary objectives in the LUCENT-1 ulcerative colitis Phase 3 study, according to a March announcement from Lilly. The drug’s potential as a therapy for moderate to severe ulcerative colitis was assessed throughout the 12-week multicenter induction phase. The humanized monoclonal antibody attaches to the interleukin-23 p19 subunit (IL-23p19). A cytokine that promotes inflammation is interleukin-23. In March, Lilly bragged that the Phase 3 trial LUCENT-1, which used an anti-IL-23p19 monoclonal antibody, was the only one to show a reduction in bowel urgency in patients with moderate to severe ulcerative colitis. Mirikizumab can be used to treat ulcerative colitis and crohn’s disease, according to Lilly.

A recent trend in the market is the use of prodrug designing. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are a class of drugs that are among the most frequently used, prescribed, and over-the-counter (OTC) drugs for the treatment of inflammatory diseases. However, NSAIDs have several undesirable side effects, the most significant of which are ulcerogenicity, mucosal hemorrhage, and gastritis. The majority of NSAID moieties are chemically made up of carboxylic functional groups, which can be one of the causes of mucosal lining injury. The prodrug designing is one of the methods used to get around this problem. So, in the past ten years, medicinal chemists have focused a lot of their emphasis on designing and synthesizing NSAID prodrugs. The prodrug concept was developed to temporarily inhibit the free carboxylic group found in NSAIDs until their systemic absorption.

Get a sample of the report @ https://www.emergenresearch.com/request-sample/1299

Key Players operating in the industry are:

AbbVie Inc., Johnson & Johnson Private Limited, Bristol-Myers Squibb Company, Merck & Co., Inc., Pfizer Inc., Novartis AG, GSK plc, Lilly, Amgen Inc., Biogen, Others

Some Key Highlights From the Report

Anti-inflammatory biologics segment accounted for the largest revenue share in 2021. Before the body experiences or recognizes inflammatory signs, a number of metabolic steps take place. A biologic drug stops the inflammatory process in its tracks by directly targeting and inhibiting a specific reaction. Traditional drugs, in contrast to biologics, only treat general inflammation once it has begun (together with its accompanying symptoms, such as joint pain). When traditional NSAIDs (such as ibuprofen) or Disease-Modifying Antirheumatic Drugs (DMARDs) (such as methotrexate) are ineffective, patients with inflammatory autoimmune diseases including rheumatoid arthritis and ankylosing spondylitis can be prescribed biologic medicines. In addition to these traditional medications, biologics can be used. A biologic target is categorized based on where the inflammation is in the process.
Injection segment accounted for the largest revenue share in 2021. The market for anti-inflammatory biologics is anticipated to an increase in revenue as a result of the rising adoption of biologics. A special and effective type of medication known as a biologic that is given through injections reduces or stops dangerous inflammation. Biologics and biosimilars are specialized classes of DMARD. Usually, they are recommended after conventional DMARDs have failed. These powerful drugs are very effective in treating many individuals with autoimmune, and inflammatory arthritis, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and others. Since they are more challenging to produce than conventional DMARDs, they can be more expensive than many of the treatments an individual takes. While some medications can be provided via self-administered shots, others need Intravenous (IV) infusions performed in a doctor’s office.

Request a discount on the report @ https://www.emergenresearch.com/request-discount/1299

Autoimmune inflammatory diseases segment accounted for the largest revenue share in 2021. The increased incidence of psoriasis, inflammatory bowel disorders, and rheumatoid arthritis all contribute to the growth of this segment. Globally, the prevalence of RA between 1980 and 2019 was 460 per 100,000 individuals, with regional differences related to research design and location. Up to 14 million instances of rheumatoid arthritis can exist globally, according to WHO. Psoriasis affects individuals of all ages and from all countries. According to estimates, psoriasis affects between 0.09% and 11.43% of the world’s population, making it a serious global problem that affects at least 100 million individuals. The World Psoriasis Day collaboration estimates that 125 million people globally, or 2 to 3% of the population, have psoriasis.
North America accounted for the largest revenue share in 2021 attributed to increasing initiatives to turn patients on to NSAIDs instead of opioids as they lead to addiction in this region. Dental pain is one example of this. Although Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are advised by the American Dental Association for pain management, opioids are nevertheless used more frequently than alternatives. However, more and more programmes are being launched to end this situation. NSAIDs that are prescribed include Advil (ibuprofen), Aleve (naproxen), and Celebrex (celecoxib). However, Rochester dentists claim that frequently, an individual’s medical history makes it impossible for them to be treated with NSAIDs. Following that, they employed a “multimodal” approach to pain management that included “NSAIDs, acetaminophen, and gabapentin.” This array of alternatives is supposed to fill the hole left when opioids are no longer used.
On 18 August, 2022, Strides Pharma announced that the U.S. Food and Drug Administration (USFDA) has given its Naproxen Sodium Softgel Capsules the go-ahead. A nonsteroidal anti-inflammatory medicine called naproxen sodium softgel capsules is used to treat pain or inflammation brought on by ailments including arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps. Acute pain brought on by other disorders can also be treated with it. Naproxen Sodium Softgel Capsules have an estimated USD 100 million US OTC market.

To know more about the report, visit @ https://www.emergenresearch.com/industry-report/anti-inflammatory-drugs-market

Emergen Research has segmented global anti-inflammatory drugs market on the basis of drug class, route of administration, application, and region:

Drug Class Outlook (Revenue, USD Billion; 2019-2030)
- Anti-Inflammatory Biologics
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Corticosteroids

Route of Administration Outlook (Revenue, USD Billion; 2019-2030)
- Oral
- Injection
- Inhalation
- Topical

Application Outlook (Revenue, USD Billion; 2019-2030)
- Autoimmune Inflammatory Diseases
  1. Rheumatoid Arthritis
  2. Psoriasis
  3. Others
- Respiratory Diseases
- Others

Request customization of the report @ https://www.emergenresearch.com/request-for-customization/1299

Regional Outlook (Revenue, USD Billion; 2019-2030)

- North America
  1. U.S.
  2. Canada
  3. Mexico
- Europe
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Benelux
  7. Rest of Europe
- Asia Pacific
  1. China
  2. India
  3. Japan
  4. South Korea
  5. Rest of APAC
- Latin America
  1. Brazil
  2. Rest of LATAM
- Middle East & Africa
  1. Saudi Arabia
  2. UAE
  3. South Africa
  4. Turkey
  5. Rest of MEA

Radical Features of the Anti Inflammatory Drugs Market Report:

The report encompasses Anti Inflammatory Drugs market overview along with market share, demand and supply ratio, production and consumption patterns, supply chain analysis, and other ley elements
An in-depth analysis of the different approaches and procedures undertaken by the key players to conduct business efficiently
Offers insights into production and manufacturing value, products and services offered in the market, and fruitful information about investment strategies
Supply chain analysis along with technological advancements offered in the report
The report covers extensive analysis of the trends, drivers, restraints, limitations, threats, and growth opportunities in the Anti Inflammatory Drugs industry

Thank you for reading our report. Customization of the report is available. To know more, please connect with us, and our team will ensure the report is customized as per your requirements.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing Marketresearch and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Visit for More Insights: https://www.emergenresearch.com/insights

Explore Our Custom Intelligence services | Growth Consulting Services

Latest Reports: Cloud Storage Market, Collagen and Gelatin Market